GMAT Question of the Day - Daily to your Mailbox; hard ones only

 It is currently 21 Feb 2019, 12:21

### GMAT Club Daily Prep

#### Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

## Events & Promotions

###### Events & Promotions in February
PrevNext
SuMoTuWeThFrSa
272829303112
3456789
10111213141516
17181920212223
242526272812
Open Detailed Calendar

February 21, 2019

February 21, 2019

10:00 PM PST

11:00 PM PST

Kick off your 2019 GMAT prep with a free 7-day boot camp that includes free online lessons, webinars, and a full GMAT course access. Limited for the first 99 registrants! Feb. 21st until the 27th.
• ### Free GMAT RC Webinar

February 23, 2019

February 23, 2019

07:00 AM PST

09:00 AM PST

Learn reading strategies that can help even non-voracious reader to master GMAT RC. Saturday, February 23rd at 7 AM PT

# Most of the Pharmaceutical Companies feel hesitant in publishing infor

Author Message
TAGS:

### Hide Tags

Verbal Forum Moderator
Joined: 15 Apr 2013
Posts: 181
Location: India
Concentration: General Management, Marketing
GMAT Date: 11-23-2015
GPA: 3.6
WE: Science (Other)
Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

### Show Tags

05 Feb 2014, 02:20
2
00:00

Difficulty:

45% (medium)

Question Stats:

65% (01:56) correct 35% (02:01) wrong based on 463 sessions

### HideShow timer Statistics

Most of the Pharmaceutical Companies feel hesitant in publishing information about clinical trials at free online databases, asserting doing this would reveal their product “Business Strategy” to competitors. Indeed, invaluable confidential information which otherwise could not be accessed by competitors, offers serious threat to a Pharmaceutical Companies. Therefore the policy of publication of clinical trial results at free online databases should be withdrawn.

Which of the following (if true) would most likely weaken the conclusion?

(A) If Business Strategy is often build well before the planning of clinical trial
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval
(D) Clinical trial conduct often differ from company to company
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success
Magoosh GMAT Instructor
Joined: 28 Dec 2011
Posts: 4486
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

### Show Tags

06 Feb 2014, 13:16
vikasbansal227 wrote:
Most of the Pharmaceutical Companies feel hesitant in publishing information about clinical trials at free online databases, asserting doing this would reveal their product “Business Strategy” to competitors. Indeed, invaluable confidential information which otherwise could not be accessed by competitors, offers serious threat to a Pharmaceutical Companies. Therefore the policy of publication of clinical trial results at free online databases should be withdrawn.
Which of the following (if true) would most likely weaken the conclusion?
(A) If Business Strategy is often build well before the planning of clinical trial
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval
(D) Clinical trial conduct often differ from company to company
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success

Dear vikasbansal227,
I'm happy to respond.

This question is a complete disaster. Among the flaws
(1) idiom mistake: "hesitant in publishing" should be "hesitant to publish"
(2) it seems "Pharmaceutical Companies" is construed as plural; why it is capitalized is anyone's guess, but using the singular article before this noun makes no sense: "threat to a Pharmaceutical Companies
(3) the "if" at the beginning of choice (A) makes no sense

On the GMAT, and in all high quality test prep sources, the quality of the language in a GMAT CR or RC practice problem adheres to the high standards held in GMAT SC.

Those are my thoughts.
Mike
_________________

Mike McGarry
Magoosh Test Prep

Education is not the filling of a pail, but the lighting of a fire. — William Butler Yeats (1865 – 1939)

Manager
Status: Oh GMAT ! I give you one more shot :)
Joined: 14 Feb 2013
Posts: 76
Location: United States (MI)
Concentration: General Management, Technology
GMAT 1: 580 Q44 V28
GMAT 2: 690 Q49 V34
GPA: 3.5
WE: Information Technology (Computer Software)
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

### Show Tags

07 Feb 2014, 09:16
1
vikasbansal227 wrote:
Most of the Pharmaceutical Companies feel hesitant in publishing information about clinical trials at free online databases, asserting doing this would reveal their product “Business Strategy” to competitors. Indeed, invaluable confidential information which otherwise could not be accessed by competitors, offers serious threat to a Pharmaceutical Companies. Therefore the policy of publication of clinical trial results at free online databases should be withdrawn.
Which of the following (if true) would most likely weaken the conclusion?
(A) If Business Strategy is often build well before the planning of clinical trial
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval
(D) Clinical trial conduct often differ from company to company
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success

Ignoring the obvious grammatical issues with the questions and options, the answer must be C

(A) Business Strategy is often build well before the planning of clinical trial - This is a strengthener. As the strategies are made well before clinical trial, in case rivals copy the secrets then there won't be any time to alter the strategy to counter it.
(B) Competitors have access to the online databases - Another strengthener, if competitors have access to the data then they can copy the product.
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval - This is a weakener, if the product is approved before the trial data is published then there is no chance for competitors to copy the product.
(D) Clinical trial conduct often differ from company to company - Has no impact on the conclusion, even though the trial differs still competitors can copy the trial process of a company.
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success - Just a general statement, has no impact on the conclusion.
_________________

Life is a highway
I wanna ride it all night long

Intern
Joined: 18 Jul 2018
Posts: 30
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

### Show Tags

23 Oct 2018, 01:35
I did not understood the question.Can someone please explain?

Posted from my mobile device
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor   [#permalink] 23 Oct 2018, 01:35
Display posts from previous: Sort by